Total Payments
$33,373
2024 Payments
$899.45
Companies
47
Transactions
533
Medicare Patients
19,655
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$15,825 (47.4%)
Food & Beverage$11,328 (33.9%)
Travel$5,981 (17.9%)
Education$239.40 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,750 | 14 | 47.2% |
| Food and Beverage | $11,328 | 505 | 33.9% |
| Travel and Lodging | $5,981 | 10 | 17.9% |
| Education | $239.40 | 3 | 0.7% |
| Entertainment | $74.71 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17,152 | 41 | $0 (2023) |
| Boston Scientific Corporation | $5,395 | 29 | $0 (2023) |
| Medtronic Vascular, Inc. | $2,602 | 8 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,368 | 87 | $0 (2024) |
| Amgen Inc. | $989.79 | 50 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $852.44 | 74 | $0 (2024) |
| Astellas Pharma US Inc | $419.75 | 19 | $0 (2019) |
| PFIZER INC. | $396.70 | 24 | $0 (2024) |
| Merck Sharp & Dohme LLC | $361.88 | 25 | $0 (2023) |
| Gilead Sciences, Inc. | $314.13 | 30 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $899.45 | 43 | Novartis Pharmaceuticals Corporation ($308.72) |
| 2023 | $2,788 | 68 | Boston Scientific Corporation ($1,624) |
| 2022 | $1,072 | 48 | Medtronic, Inc. ($157.71) |
| 2021 | $934.87 | 55 | Novartis Pharmaceuticals Corporation ($193.19) |
| 2020 | $280.95 | 17 | Amgen Inc. ($117.54) |
| 2019 | $17,030 | 101 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($13,430) |
| 2018 | $5,440 | 117 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($1,848) |
| 2017 | $4,928 | 84 | BOSTON SCIENTIFIC CORPORATION ($2,143) |
All Payment Transactions
533 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $43.64 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.04 | General |
| Category: Cardiovascular | ||||||
| 11/12/2024 | Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: Cardio-renal | ||||||
| 10/17/2024 | IDORSIA PHARMACEUTICALS US INC | Tryvio (Drug) | Education | In-kind items and services | $60.41 | General |
| Category: Hypertension | ||||||
| 09/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: DIABETES | ||||||
| 09/23/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $30.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $10.35 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/10/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Diabetes | ||||||
| 09/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $33.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/29/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $31.26 | General |
| 08/29/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $29.65 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/20/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/05/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.68 | General |
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $18.15 | General |
| Category: Cardiovascular | ||||||
| 07/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $10.43 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $14.28 | General |
| 06/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $10.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 4,658 | 8,303 | $1.9M | $442,789 |
| 2022 | 33 | 5,086 | 8,618 | $2.1M | $572,638 |
| 2021 | 29 | 4,931 | 7,152 | $1.8M | $544,658 |
| 2020 | 29 | 4,980 | 7,482 | $1.7M | $530,329 |
Total Patients
19,655
Total Services
31,555
Medicare Billing
$2.1M
Procedure Codes
128
All Medicare Procedures & Services
128 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 788 | 1,177 | $280,385 | $106,416 | 38.0% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 74 | 75 | $365,145 | $78,149 | 21.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 462 | 465 | $338,971 | $60,667 | 17.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 112 | 112 | $179,066 | $36,384 | 20.3% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 75 | 91 | $91,565 | $27,128 | 29.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 147 | 592 | $130,865 | $25,626 | 19.6% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 107 | 107 | $91,845 | $17,283 | 18.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 63 | 123 | $32,925 | $10,976 | 33.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 694 | 955 | $49,077 | $9,761 | 19.9% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 192 | 193 | $49,701 | $9,497 | 19.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $24,762 | $9,121 | 36.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 55 | 57 | $19,114 | $7,232 | 37.8% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 116 | 119 | $63,484 | $6,254 | 9.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 293 | 732 | $29,953 | $5,729 | 19.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 509 | 651 | $11,067 | $5,468 | 49.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 52 | 56 | $16,851 | $5,177 | 30.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 36 | $18,629 | $4,728 | 25.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 67 | 67 | $17,035 | $3,411 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 20 | 38 | $9,052 | $2,672 | 29.5% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2023 | 29 | 56 | $12,929 | $1,973 | 15.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 291 | 323 | $9,690 | $1,870 | 19.3% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 81 | 84 | $8,232 | $1,531 | 18.6% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 15 | 15 | $5,894 | $1,221 | 20.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 16 | 16 | $3,315 | $1,189 | 35.9% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 14 | 14 | $5,056 | $911.33 | 18.0% |
About Dr. Mubashar Khan, M.D
Dr. Mubashar Khan, M.D is a Cardiovascular Disease healthcare provider based in Camden, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2014. The National Provider Identifier (NPI) number assigned to this provider is 1497175707.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mubashar Khan, M.D has received a total of $33,373 in payments from pharmaceutical and medical device companies, with $899.45 received in 2024. These payments were reported across 533 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($15,750).
As a Medicare-enrolled provider, Khan has provided services to 19,655 Medicare beneficiaries, totaling 31,555 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 128 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Camden, NJ
- Active Since 04/25/2014
- Last Updated 04/25/2014
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1497175707
Products in Payments
- LifeVest (Device) $17,152
- WATCHMAN (Device) $3,771
- Reveal LINQ (Device) $2,602
- WATCHMAN Access System (Device) $1,599
- ENTRESTO (Drug) $1,019
- XARELTO (Drug) $872.22
- Repatha (Biological) $613.07
- ELIQUIS (Drug) $438.15
- Corlanor (Drug) $365.02
- VERQUVO (Drug) $361.88
- LEQVIO (Drug) $349.60
- Adempas (Drug) $232.19
- LEXISCAN (Drug) $222.24
- Vascepa (Drug) $221.08
- PRALUENT (Biological) $202.25
- ONYX FRONTIER (Device) $157.71
- Penumbra Ruby Coil (Device) $154.88
- JARDIANCE (Drug) $154.68
- Ozempic (Drug) $153.07
- CAMZYOS (Drug) $149.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Camden
Dr. Perry Weinstock, M.d, M.D
Cardiovascular Disease — Payments: $257,830
Cardiovascular Disease $257,830
Zoltan Turi, Md, MD
Cardiovascular Disease — Payments: $28,055
Cardiovascular Disease $28,055
Dr. Devinder Singh, M.d, M.D
Cardiovascular Disease — Payments: $21,241
Cardiovascular Disease $21,241
Dr. Brian Corbett, D.o, D.O
Cardiovascular Disease — Payments: $16,931
Cardiovascular Disease $16,931
Kathleen Heintz, Do, DO
Cardiovascular Disease — Payments: $10,143
Cardiovascular Disease $10,143
Dr. Matthew Ortman, M.d, M.D
Cardiovascular Disease — Payments: $9,897
Cardiovascular Disease $9,897